|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study was undertaken to conduct a comprehensive investigation of the role of DNA damage repair (DDR) defects in poor outcome ER<sup>+</sup> disease.<b>Experimental Design:</b> Expression and mutational status of DDR genes in ER<sup>+</sup> breast tumors were correlated with proliferative response in neoadjuvant aromatase inhibitor therapy trials (discovery dataset), with outcomes in METABRIC, TCGA, and Loi datasets (validation datasets), and in patient-derived xenografts.
|
29793947 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase activity in extragonadal sites contributes to this source of estrogen and may contribute to breast tumor development and/or growth.
|
11795380 |
2001 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase activity has been demonstrated in breast tissue in vitro, and expression of aromatase is highest in or near breast tumor sites.
|
11897504 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aromatase activity has been demonstrated in breast tissue in vitro, and expression of aromatase is highest in or near breast tumor sites.
|
11897504 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase transcript expression and enzyme activity in breast tumor tissue is greater than that in the normal breast tissue, and prostaglandins can increase CYP19 expression and aromatase activity in breast cancer cells.
|
16498361 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase transcript expression and activity in breast tumor tissue is greater than that in the normal breast tissue, and prostaglandins can increase CYP19 expression and aromatase activity in breast cancer cells.
|
16712450 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Aromatase is an estrogen synthetase.Estrogens are female sex hormones involved in the development and growth of breast tumors.
|
19250198 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase is the rate-limiting enzyme in estrogen biosynthesis and its expression in breast adipose stromal cells is hypothesized to drive the growth of breast tumors and confer resistance to endocrine therapy in obese postmenopausal women.
|
30851382 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Aromatase is present in human breast tumors and in breast cancer cell lines suggesting the possibility of in-situ estrogen production via the androstenedione to estrone and estradiol pathway.
|
8476772 |
1993 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
|
17975727 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
|
17562079 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
|
24669750 |
2014 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar magnitude suggestive association, although nonstatistically significant, was found between Val(80) polymorphism and estrogen receptor-negative status of the breast tumors.
|
19366906 |
2009 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
|
18245543 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
|
28112739 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Agents that inhibit Cox-2 or block the biological effects of PGE2 may be useful in significantly limiting aromatase activity and proliferation of human breast tumor cells regardless of the presence of Cox-2.
|
16997132 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears.
|
11935306 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
|
15862961 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As tamoxifen via GPER induced aromatase expression also in CAFs, this pathway may be involved in promoting aggressive behavior of breast tumors in response to tamoxifen treatment.
|
24928526 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.
|
23342035 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Basal aromatase activity and the degree of aromatase stimulation by these factors were greater in fibroblasts derived from 'normal' breast tissue than from breast tumours.
|
10731102 |
1999 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because the expression of aromatase in breast cancer tissues is driven by unique promoters I.3 and II, a more complete understanding of the regulatory mechanism of aromatase expression through promoters I.3/II in breast tumors should be valuable in developing targeted therapies, which selectively suppress estrogen production in breast tumor tissue.
|
18519709 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Biology of aromatase in the mammary gland.
|
14973387 |
2000 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
|
24923427 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cell culture including MCF-7 breast cancer cells, animal experiments using aromatase-transfected breast cancer cells, and transgenic mouse studies have demonstrated that estrogen production in situ plays a more important role than circulating estrogens in breast tumor promotion.
|
10731103 |
1999 |